Britain and America have reached a major commercial pact that will guarantee zero import taxes on British drug products going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the public health system. This move guarantees that duties on these crucial exports will remain at nothing for a duration of 36 months.
This development is in response to recent statements to dramatically increase duties on branded pharmaceutical imports, with figures mentioned as high as double the cost.
"This arrangement between the UK strengthens the global environment for innovative medicines and brings much-needed fairness to transatlantic medicine commerce," an announcement said.
Commercial Importance
Pharmaceuticals constitute one of the Britain's largest export categories to the US, which is by far the largest destination for large UK drugmakers.
Export figures reveal that in the one-year period leading up to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure made up 17.4% of all goods exports in that timeframe.
"This deal safeguards jobs, stimulates funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a government official commented.
Key NHS Changes
The agreement entails several key pledges from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must return to the NHS to control costs will be limited at fifteen percent. Last year, refunds were more than twenty percent.
Industry Background
This agreement follows a ongoing row between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were exacerbated by claims that American patients were paying several times more for the same drugs than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been paused or cancelled, while substantial expansions have been pledged toward American operations.
The Science Minister publicly accepted that the NHS must invest a greater share on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the last ten years.
